AAPL 154.88 +1.84 (+1.20%)MSFT 105.38 +0.38 (+0.36%)FB 130.65 -2.52 (-1.89%)ZNGA 3.95 +0.07 (+1.68%)NVDA 133.37 -0.29 (-0.22%)WBA 68.22 +0.16 (+0.24%)GOOG 1029.8 -7.78 (-0.75%)PIH 4.14 +0.25 (+6.43%)
AAPL 154.88 +1.84 (+1.20%)MSFT 105.38 +0.38 (+0.36%)FB 130.65 -2.52 (-1.89%)ZNGA 3.95 +0.07 (+1.68%)NVDA 133.37 -0.29 (-0.22%)WBA 68.22 +0.16 (+0.24%)GOOG 1029.8 -7.78 (-0.75%)PIH 4.14 +0.25 (+6.43%)

Cash Flow ABUS Quote Arbutus Bio

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
NetIncome -61 -384 -84
Depreciation 1 1 2
DeferredIncomeT -16 -105 -24
StockBasedCompe 22 39 15
AccountsReceiva 1 1 0
InventoryCS 0 0 0
AccountsPayable 0 0 0
OtherWorkingCap -15 -1 4
OtherNonCashIte -25 0 -1
NetCashProvided -55 -58 -49
InvestmentsInPP -2 -4 -7
AcquisitionsNet 0 0 0
PurchasesOfInve 0 -13 0
SalesMaturities 0 0 0
PurchasesOfInta 0 0 0
OtherInvestingA 10 -83 35
NetCashUsedForI 8 -99 28
DebtIssued 0 12 0
DebtRepayment 0 0 0
CommonStockIssu 142 0 0
CommonStockRepu 0 0 0
DividendPaid 0 0 0
OtherFinancingA 2 0 0
NetCashProvided 144 13 49
NetChangeInCash 95 -144 29
CashAtBeginning 72 167 23
CashAtEndOfPeri 167 22 52
Arbutus Biopharma Corporation income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Arbutus Biopharma Corporation FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.